A Phase II, Open-Label, Multicenter, Multicohort Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors

Trial Profile

A Phase II, Open-Label, Multicenter, Multicohort Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
  • Indications Head and neck cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 28 Jun 2018 Planned End Date changed from 11 Oct 2019 to 10 Sep 2020.
    • 28 Jun 2018 Planned primary completion date changed from 14 Sep 2018 to 18 Jul 2019.
    • 24 Jun 2018 Planned number of patients changed from 120 to 250.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top